Nintedanib

證據等級: L5

預測適應症: 3 個

Nintedanib: From an Unrecorded Original Indication to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nintedanib's original approved indication is not recorded in this evidence pack (data gap). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), with 0 clinical trials and 1 supporting publication currently identified — evidence remains at the mechanistic/preclinical level.

Quick Overview

Item	Content
Original Indication	Not available (data gap — no records in evidence pack)
Predicted New Indication	Dermatofibrosarcoma Protuberans
TxGNN Prediction Score	99.15%
Evidence Level	L4 (preclinical / mechanism-level only)
Taiwan Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Nintedanib is not available in this evidence pack (DG002, High severity). Based on the mechanistic rationale that is available, Nintedanib is described as a PDGFR-α/β inhibitor among its targets.

DFSP tumors are driven by a COL1A1-PDGFB fusion gene that causes constitutive PDGFRB activation. This overlaps mechanistically with Imatinib, the current standard of care for DFSP. Nintedanib's PDGFR inhibitory activity provides a plausible target-based rationale for this prediction, and the very high TxGNN score (0.9915) reflects strong network-level support. However, the only supporting literature identified (PMID 29408302) is a general review of PDGFR inhibitors as a drug class — it does not report Nintedanib-specific data in DFSP, and no clinical trials currently exist for this indication.

The other two predicted indications (liposarcoma, ovarian myxoid liposarcoma) are considerably weaker: both are pure TxGNN score-based extrapolations from the same PDGFR/FGFR pathway logic, with no supporting literature or trials at all (Evidence Level L5, recommendation "Hold" for both), and are not discussed further here.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Review	Pharmacological Research	Reviews the role of small-molecule PDGFR inhibitors (as a drug class) in treating neoplastic disorders; establishes PDGFR signaling as a therapeutic target but does not report Nintedanib-specific DFSP data.

Taiwan Market Information

Nintedanib is not currently marketed in Taiwan (0 authorizations on record). No license or approved-indication data is available for this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA label/warning data (DG001) is flagged as a Blocking data gap — its absence directly prevents entry into the S1 safety pre-assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale: The DFSP prediction rests on a plausible but indirect mechanistic argument (PDGFR pathway overlap with Imatinib) supported by a single drug-class review paper, with no Nintedanib-specific trials or preclinical data, and no original indication or MOA confirmed on file. A Blocking safety data gap (TFDA label unavailable) also prevents formal S1 safety evaluation.

To proceed, the following is needed:

TFDA/package insert data to resolve the Blocking safety gap (DG001)
Confirmed MOA and original approved indication(s) for Nintedanib from DrugBank (DG002)
Nintedanib-specific preclinical (e.g., PDGFRB-fusion cell line/xenograft) or case-level clinical data in DFSP
Re-evaluation of liposarcoma and ovarian myxoid liposarcoma predictions if any supporting literature emerges (currently no basis to proceed)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.